stockportfolio.pro
CME vs MRSH: Which Stock Is the Better Buy?
CME Group Inc. and Marsh & McLennan Companies, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Financial Services.
AI verdict — CME vs MRSH, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| CME Group Inc. (CME) | Marsh & McLennan Companies, Inc. (MRSH) | |
|---|---|---|
| Market cap | $85.5B | $86.0B |
| Revenue (latest FY) | $6.52B | $26.98B |
| Net income (latest FY) | $4.02B | $4.16B |
| Revenue growth (5y CAGR) | 6.0% | 9.4% |
| Net margin | 61.7% | 15.4% |
| Return on equity | 14.0% | 27.2% |
| P/E ratio | 20.2 | 22.3 |
| Dividend yield | 2.2% | 2.0% |
| Profitable years (of last 10) | 10 | 10 |
| Positive free cash flow | Yes | Yes |
See the full CME vs MRSH breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open CME's full financials → Open MRSH's full financials →Frequently asked questions
Which is bigger, CME or MRSH?
Marsh & McLennan Companies, Inc. is larger by market capitalization — $86.0B versus $85.5B.
Which grows faster, CME or MRSH?
Over the last five fiscal years, Marsh & McLennan Companies, Inc. grew revenue faster — 9.4%/yr versus 6.0%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.